Cord Blood CD133+ Stem/Progenitor Cells, Pooled Donors, Frozen

Human cord blood CD133+ stem and progenitor cells are positively selected using immunomagnetic anti-CD133 (clone AC133) microbeads from the mononuclear cell fraction. Pooled CD133+ cells are from two or more donors and are available in larger lots. Isolated cells are characterized by flow cytometry prior to cryopreservation to ensure a highly pure and viable cell population.

Cord blood is collected from mothers that are negative for HIV, HepB, and HepC during pregnancy. Testing on cord blood can be provided as a custom order.

Since our founding in 2010, CGT Global has pursued our mission to transform healthcare as we accelerate cell and gene therapy research and clinical trials, streamline the commercialization of new treatments, and map the last mile to patient access to these life-changing remedies.  By innovating each stage in the cycle; development, commercialization, and delivery, we reduce the overall cost of the care and multiply access points so that millions can receive cutting edge, life-saving gene and cell therapies.

CGT Global - Landing Page Desktop Prototype

Description

Human CD133 is a transmembrane glycoprotein that is expressed on CD34+ and CD34– multipotent stem and progenitor cells that are involved in hematopoiesis. Unlike CD34+ cells, cord blood CD133+ cells are also expressed on circulating endothelial precursors that are involved in vasculogenesis. Additionally, cord blood CD133+ hematopoietic cells have been found to differentiate in vitro to cells of the ectodermal and mesodermal lineages implying that these cells have the ability to give rise to cells of non-hematopoietic lineages.

Cells were obtained using Institutional Review Board (IRB) approved consent forms and protocols.

Additional information

Anticoagulant

Format

Grade

Species

Cell and Tissue Source

Disease State

Donor Attributes

Product Information Sheet

CB CD133 Pooled – Frozen

Material Safety Data Sheet

Cord Blood – Frozen